Efficacy of oral zinc therapy in epidermodysplasia verruciformis with squamous cell carcinoma

Sharma, Sudhanshu; Barman, Krishna Deb; Sarkar, Rashmi; Manjhi, Mukesh; Garg, Vijay Kumar

doi:10.4103/2229-5178.126034

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zinc was proven to be used as topical or systemic oral therapy in previous studies for treatment of warts [ 29 , 30 ]. Only few studies used it intralesional and showed favorable results as those done by (Mohamed [ 7 ] , Moubasher [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts

2022

View full text Add to dashboard Cite

Immunotherapy represents a promising therapeutic option for treatment of warts. Different concentrations of Candida antigen (1/100 and 1/1000) and zinc sulfate 2% were not previously compared regarding their efficacy in treatment of cutaneous warts. The present study compared the safety and efficacy of intralesional candida antigen versus intralesional 2% zinc sulfate for treatment of cutaneous warts. This prospective controlled clinical trial included one hundred and five patients presented with common, plantar, and plane warts. Patients were divided randomly into three groups, each group included 35 patients. Group 1 were treated with intralesional candida antigen (Ag) 1/100, Group 2 were treated with intralesional candida Ag 1/1000, and Group 3 were treated with intralesional zinc sulfate 2%. This study found that target warts of group 1 displayed higher rate of complete clearance compared to group 2 and group 3 (94.3%, 77.1, 74.2%), respectively. The present study concluded that intralesional immunotherapy with Candida antigen was more effective than Intralesional 2% zinc sulfate in treatment of cutaneous warts and less painful. Clinical trial registration number is (Clinical Trials.gov Identifier: NCT03158168).

show abstract

Section: Discussionmentioning

confidence: 99%

Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts

2022

View full text Add to dashboard Cite

show abstract

“…Patients should be advised to use sunblock from childhood [ 2 ]. In another case, zinc therapy was used for treating EV, with a response rate of 20% to 40%, without a recurrence after six months [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Epidermodysplasia Verruciformis: A Rare Case Report

Alshammari

Al-Issa²,

Ghobara³

2020

Cureus

View full text Add to dashboard Cite

Epidermodysplasia verruciformis (EV) is an uncommon disorder that is transmitted in an autosomal recessive manner. It is characterized by increased susceptibility to human papillomavirus (HPV) infection, which presents with hypo-or hyperpigmented macular lesions, pityriasis versicolor-like lesions, and an early tendency to transform into skin cancer. We present a case of a 36-year-old female with complaints of asymptomatic, multiform lesions over the face, neck, chest, and upper arms. Histopathology was suggestive of EV, and our patient was given oral isotretinoin 20 mg/day and advised strict photoprotection.

show abstract

“…In an open-label study in Korea, the effectiveness of oral zinc sulfate 10 mg/kg for 2 months in the treatment of patients with nongenital viral warts was assessed and 50% of patients showed a complete resolution ( Mun et al, 2011 ). Sharma et al (2014) reported the clearance of recalcitrant warts in a patient with epidermodysplasia verruciformis in 12 weeks with oral zinc (10 mg/kg/day). In addition, some evidence showed that a combination therapy of oral zinc sulfate with conventional treatments of vulvar warts appeared to reduce the relapse rate of genital warts ( Akhavan et al, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial

Mahmoudi

Ghodsi

Tavakolpour

et al. 2018

International Journal of Women's Dermatology

View full text Add to dashboard Cite

BackgroundCutaneous warts are caused by a small group of specific types of human papillomaviruses. Cryotherapy is a highly effective treatment for patients with viral warts; however, it is a painful method and usually requires several treatment sessions. Zinc is a trace element with many proven effects on the immune system.ObjectiveOur aim was to assess the efficacy and safety of oral zinc sulfate in the treatment and recurrence rate of common warts.MethodsEighty-three patients with common warts participated in this double-blind, randomized, placebo-controlled trial. In both groups, three sessions of liquid nitrogen cryotherapy were performed for up to 2 months with 3-week intervals. The treatment group (n = 45) received oral zinc sulfate capsules in a dose of 10 mg/kg per day up to 600 mg day. The control group (n = 38) was provided with placebo of similar appearance. Treatment continued for 2 months and the follow-up period lasted up to 6 months.ResultsWarts completely resolved in 26 patients in the treatment group (68.4%) and 23 patients in the placebo group (63.9%; p = .68). Three patients (7.9%) in the treatment group and six patients (16.6%) in the placebo group has a recurrence of the warts (p = .19).ConclusionAccording to our study, the addition of zinc to cryotherapy was not beneficial in the treatment of patients with common warts nor did it prevent recurrences.

show abstract

Efficacy of oral zinc therapy in epidermodysplasia verruciformis with squamous cell carcinoma

Cited by 8 publications

References 14 publications

Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts

Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts

Epidermodysplasia Verruciformis: A Rare Case Report

Cryotherapy plus oral zinc sulfate versus cryotherapy plus placebo to treat common warts: A double blind, randomized, placebo-controlled trial

Contact Info

Product

Resources

About